When a treatment is described as regenerative, ask for the exact product and proposed use before evaluating the claim. A clinic’s registration, a study listing and a product approval are different things. None should be substituted for another, and an approval for one condition does not establish approval for a different condition.
This checklist is for checking information, not selecting a treatment or certifying a clinic’s regulatory status. Bring unresolved questions to the treating clinician and, when needed, FDA. If discussing care with Dr. Fred Bloem’s office, ask for the same product-specific documentation rather than relying on a general service description.
Identify the actual product and proposed use
Request the product’s proper or trade name, manufacturer, source and intended route of administration. Write down the condition it is being offered to treat and the patient group involved. Broad terms such as stem cells, exosomes or regenerative injections are not enough to identify a specific regulated product.
Ask which regulatory pathway applies and what documents support that explanation. Regulatory requirements can depend on the product, processing and intended use; this checklist does not decide whether a particular offering qualifies for an exception or is lawfully marketed.
Check approval at the product and indication level
Use current FDA product information and the relevant label, not a clinic logo or certificate alone. For cellular and gene therapies, the FDA maintains an approved-products list. Match the name and manufacturer, then check the approved indication and limitations in the product information.
For example, FDA’s RYONCIL page identifies remestemcel-L-rknd for steroid-refractory acute graft-versus-host disease in pediatric patients aged two months and older. Its December 2024 approval does not establish approval for unrelated joint pain, anti-aging or other uses. This example does not imply that Dr. Bloem’s practice offers RYONCIL.
Older summaries can become outdated. Do not repeat a blanket statement that the only approved stem-cell products are cord-blood products without checking current FDA information. Also avoid assuming that approval guarantees an individual benefit or absence of risk.
Registration is not product approval
A registration number or product listing is not the same as FDA’s approval of the proposed treatment. FDA’s patient information on regenerative products warns that facility registration and ClinicalTrials.gov listings can be presented in misleading ways.
Ask precisely what a document establishes. Does it identify a registered establishment, a listed product, an authorized study or an approved product and indication? Keep those answers separate. A billing code, testimonial or professional credential is not a substitute for the relevant product information.
A clinical-trial listing does not establish approval
If a treatment is offered as research, request the study identifier, sponsor, location, eligibility criteria, study contact and consent information. Compare the offered product, procedure and site with the actual study record. A listing on ClinicalTrials.gov does not by itself demonstrate FDA approval or establish that the marketed offering is part of that study.
Ask the study team to explain applicable FDA oversight and ethics review, and how questions or adverse events are handled. Do not assume that an Investigational New Drug application is marketing approval or that its existence can be verified simply by locating a study online. Seek clarification from the responsible study contact or FDA if the explanation is unclear.
Evaluate safety and evidence separately
Regulatory status is one question; the evidence for the proposed benefit and the risks for you are additional questions. Ask for the actual research, comparison group, outcomes, follow-up period and limitations. Testimonials or a plausible biological mechanism do not establish clinical effectiveness.
FDA’s 2026 warning about unapproved human-cell or tissue products describes serious safety concerns. Products described as natural, donor-derived or taken from one’s own body should not be assumed risk-free. Discuss relevant risks, alternatives and monitoring with a qualified clinician.
Keep a written decision checklist
Exact product, manufacturer and proposed use.
Current FDA source and the specific status claimed.
Study details if participation in research is proposed.
Evidence for the claimed benefit and important uncertainties.
Risks, alternatives, costs, follow-up and a contact for concerns.
If the documents do not match the offer, pause and seek clarification before consenting or paying. This checklist does not replace informed consent or a personalized clinical assessment.
Does FDA registration mean a treatment is approved?
No. Ask for product- and use-specific documentation.
Does an approved product have approval for every proposed use?
No. Check the current label and ask the clinician to explain how the proposed use relates to it.
Does a trial listing prove safety or effectiveness?
No. Research participation and product approval are distinct, and studies have their own risks and uncertainties.
